ACT Capital Management’s PDS Biotechnology PDSB Stock Holding History

ACT Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.4K	Hold	30,000	–	–	0.02%	62
2026 Q1	$18.1K	Hold	30,000	–	–	0.01%	56
2025 Q4	$23.1K	Buy	+30,000	New	+$27.1K	0.02%	57
2022 Q3	$36K	Hold	12,000	–	–	0.05%	60
2022 Q2	$44K	Sell	12,000 -48,000	-80%	-$228K	0.06%	66
2022 Q1	$371K	Hold	60,000	–	–	0.39%	39
2021 Q4	$486K	Hold	60,000	–	–	0.35%	47
2021 Q3	$894K	Buy	60,000 +15,000	+33%	+$187K	0.46%	39
2021 Q2	$565K	Buy	+45,000	New	+$351K	0.29%	61

Other funds holding PDSB

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TWP

Tempus Wealth Planning Irvine, California $511M AUM 28.39% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

BIAS

Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.99% 1-Year Est. Return

ACT Capital Management's PDSB Position: Q2 2026 in Review

ACT Capital Management held its PDS Biotechnology (PDSB) position steady in Q2 2026 at 30,000 shares worth $26.4K. The position accounts for 0.02% of the portfolio, ranked #62.

ACT Capital Management first reported a position in PDSB in Q2 2021 and has held it in 9 quarters since. The position peaked at $894K in Q3 2021. 9 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

ACT Capital Management held 30,000 shares of PDS Biotechnology worth $26.4K as of Q2 2026.
ACT Capital Management left its PDS Biotechnology share count unchanged in Q2 2026.
PDS Biotechnology made up 0.02% of ACT Capital Management's portfolio in Q2 2026, its #62 holding.
ACT Capital Management first reported a position in PDS Biotechnology in Q2 2021 and has held it in 9 quarters since.
ACT Capital Management's PDS Biotechnology position peaked at $894K in Q3 2021.
9 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.